Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9468)	11/12/2003 12:06:24 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Press Release Source: Myriad Genetics, Inc. Myriad Genetics' Alzheimer's Drug Candidate Improves Learning Wednesday November 12, 6:15 am ET SALT LAKE CITY, Nov. 12 /PRNewswire-FirstCall/ -- MPC-7869 (R-flurbiprofen), the Alzheimer's disease drug candidate in Phase II human clinical trials being conducted by Myriad Genetics, Inc. (Nasdaq: MYGN - News), shows improved memory and spatial learning in a model of Alzheimer's disease, the Company said today. The new data from a study entitled, Chronic Treatment of Transgenic APP Mice with R-flurbiprofen, led by Dr. Todd E. Golde and associates at Mayo Clinic Jacksonville, and Dr. Edward H. Koo and associates at the University of California, San Diego, was presented at Neuroscience 2003, the annual meeting of the Society for Neuroscience, in New Orleans on November 9, 2003. The study was designed to determine whether a reduction in the toxic Abeta42 peptide leads to improvement in memory and spatial learning in a mouse model of human Alzheimer's disease. To answer this question, the authors allowed transgenic mice to age until they began to show signs of the onset of neuronal plaques and learning disabilities. This stage of impairment may be compared with mild Alzheimer's disease in humans. The mice were then treated on a long-term chronic basis with either R-flurbiprofen (significantly lowers Abeta42) or very high doses of ibuprofen (less potent Abeta42 lowering activity). Treated mice were tested for memory using the well-established Morris water maze test, a highly sensitive assessment of cognition in animals. <continued on next post>